UCLA Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Czernin, Johannes
NCT05398302: Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Recruiting
1
30
US
Image Guided Biopsy, Image-Guided Biopsy, Imaging Guided Biopsy
Jonsson Comprehensive Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
12/25
12/26
NCT02174679: 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

No Longer Available
N/A
US
68Ga DOTATATE, 68Ga DOTATATE PET/CT Scan
Jonsson Comprehensive Cancer Center
Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors
 
 
NCT02902757: FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Recruiting
N/A
50
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Glioblastoma
08/25
08/26
NCT05435495: Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting
N/A
125
US
Single-photon emission computed tomography, SPECT/CT, Blood Draw, Tumor Biopsy, Biopsy
University of California, San Francisco, National Cancer Institute (NCI), Prostate Cancer Foundation
Prostate Cancer
12/25
12/25
Allen-Auerbach, Martin
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
Schiepers, Christiaan
No trials found

Download Options